 The FDA has approved Incyte Corporations NASDAQ: INCY approved Jakafi ruxolitinib for chronic graft-versus-host disease GVHD. The approval comes for adult and pediatric patients 12 years and older with GVHD after the failure of one or two lines of systemic therapy. 